Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Study Adds Evidence on The Link Between Leukemia Cutis and Poor Prognosis in AML

May 6, 2019
By John Schieszer
News
Article

A recent study in JAMA Dermatology evaluated overall and leukemia-specific survival in patients with AML and leukemia cutis vs AML alone.

The presentation of leukemia cutis in acute myeloid leukemia (AML) may be associated with decreased overall survival and leukemia-specific survival, and these patients may require more aggressive monitoring and treatment, according to the findings of a recent study published in JAMA Dermatology.

Researchers conducted a matched-cohort, retrospective study of 1,683 patients who were diagnosed with AML between January 2005 and April 2017. The investigators analyzed data on all patients, including 78 patients with biopsy-proven leukemia cutis. The team ultimately included 62 patients with AML and leukemia cutis (mean age, 58.2 years) and matched them in a 1:3 ratio to 186 patients with AML but no leukemia cutis (mean age, 58.2 years).

The 5-year survival rate was 8.6% among the 62 patients with AML with leukemia cutis compared with 28.3% among the 186 matched patients with AML without leukemia cutis. In addition, a matched survival analysis found that patients with AML and leukemia cutis had a hazard ratio (HR) of 2.06 (95% CI, 1.26–3.38; P = .004) for leukemia-specific death compared with those without leukemia cutis; for all-cause death, the HR was 1.66 (95% CI, 1.06–2.60; P = .03). 

“There was always a belief that the presence of leukemia cutis was a poor prognostic sign, but some more recent studies were more equivocal on this. I was not surprised by the results of our study given my clinical experience caring for these patients over the last decade,” said corresponding author Milan J. Anadkat, MD, an associate professor of dermatology at Washington University School of Medicine in St. Louis, Missouri.

Anadkat reflected on the implications of these findings in an interview with Cancer Network. “I have no doubts that oncologists caring for these patients share a similar clinical impression regarding the prognosis of patients with leukemia cutis. The major take-home message is to emphasize that these leukemia subsets behave differently, and that current treatment options fall short for affected patients. Much progress has been made, but there remains work to be done,” he said.

The study indicated no differences in the odds of having secondary leukemia, NPM1 mutation, FLT3 internal tandem duplication, MLL gene rearrangement, inversion of chromosome 16, or translocation involving chromosome 8 when they compared the two groups. However, the patients with AML and leukemia cutis had higher odds of having other extramedullary organ involvement (odds ratio [OR], 3.48) and an additional chromosome 8 (OR, 2.13).

“The predilection of patients with AML and LC [leukemia cutis] to have additional sites of extramedullary involvement may reflect distinctive biological characteristics of these leukemic cells,” wrote the authors. “Further investigations are needed to understand the biological mechanisms behind leukemic infiltration of the skin and its association with patient survival, as well as to determine the most salient treatment strategies for these cases.”

Henry Fung, MD, FACP, FRCPE, vice chair of the Department of Hematology/Oncology at Fox Chase Cancer Center, said this study raises interesting questions. While it is limited by its retrospective nature and is based on only a single-institution experience, the findings may be an important first step in better understanding how areas of the skin may function as sanctuaries for leukemic cells, he said.

“This is an interesting retrospective study from a single institution with a large cohort with interesting observation,” Fung told Cancer Network. “Identifying a cohort of patients who may benefit from more intensive treatment is clinically relevant. However, having more intensive therapy may not necessarily improve treatment outcomes,” he cautioned.

Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Related Content
Advertisement

FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML

FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML

Ariana Pelosci
July 10th 2025
Article

A PDUFA date for decitabine/cedazuridine and venetoclax in newly diagnosed AML has been set for February 25, 2026.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Ariana Pelosci
July 3rd 2025
Article

The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

High Tumor Volume Confers CAR T-Cell Therapy Toxicity Risk in LBCL

Russ Conroy
June 30th 2025
Article

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.


FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

Tim Cortese
June 27th 2025
Article

The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.

Related Content
Advertisement

FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML

FDA Accepts sNDA for Decitabine/Cedazuridine Combo in Newly Diagnosed AML

Ariana Pelosci
July 10th 2025
Article

A PDUFA date for decitabine/cedazuridine and venetoclax in newly diagnosed AML has been set for February 25, 2026.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Ariana Pelosci
July 3rd 2025
Article

The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

High Tumor Volume Confers CAR T-Cell Therapy Toxicity Risk in LBCL

Russ Conroy
June 30th 2025
Article

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.


FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

FDA Removes REMS, Lessens Requirements of Liso-cel/Ide-cel in Blood Cancers

Tim Cortese
June 27th 2025
Article

The FDA had reduced driving and geographic restrictions to 2 weeks for patients with lymphomas and multiple myeloma receiving liso-cel and ide-cel.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.